Posted by Michael Wonder on 01 Jun 2021
Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults with multiple myeloma who have received at least three prior therapies and who are refractory to their last treatment.
Bristol Myers Squibb Canada today announced Health Canada has granted conditional approval for Abecma (idecabtagene vicleucel) as the first and only B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell immunotherapy for adults with multiple myeloma.
